Saving Lives – Reducing Healthcare Costs

Fast-Track to Key Company Information

Miraculins at a Glance

Lead Technology Programs

Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease.

The company’s lead technology programs – the Scout DS® Diabetes Screen and the PreVu® Skin Cholesterol Test – are point-of-care tests that screen for risk of diabetes and coronary artery disease, without needles, blood draw, fasting or waiting. Patients with elevated test results are then recommended to see their physicians for follow-up.

Both of these technologies are totally non-invasive and user-friendly. These are characteristics that can encourage individuals to get screened early and often for risk of pre-diabetes and type 2 diabetes - now being referred to by experts as the fastest growing disease in history - and for risk of coronary artery disease. 

Video Highlights

Click here to view the CTV News Report Click here to the visit the Life Science of Manitoba Video Click here to the visit the Scout DS Demonstration Video

Industry and Investing Insights

Investor Relations

Sign Up for E-Mail Updates From Miraculins

Submit Now Privacy Policy

Miraculins Lead Technologies

To go directly to the PreVu® 
website, please click here:
To go directly to the Scout DS® 
website, please click here:
Click here to the visit the PreVu web site. Miraculins Scout DS